Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy

Jin Qian, Stephen D. Brown, Susan M. Carlton

    Research output: Contribution to journalArticle

    92 Citations (Scopus)

    Abstract

    The efficacy of ketamine (KET), a non-competitive NMDA receptor-channel blocker, was assessed in relieving nociceptive behaviors in neuropathic rats with tight ligations of the L5 and L6 spinal nerves. The antinociceptive effects of KET were dose- and time-dependent. A systemic injection of 0.01 mg/kg KET transiently (15-30 min) attenuated several nociceptive behaviors, including mechanical allodynia and hyperalgesia, cold allodynia, spontaneous pain, and cold stress-induced pain. Treatment with 1.0 mg/kg KET consistently decreased all nociceptive behaviors for 45-75 min, without noticeable side effects. Higher doses (25 and 50 mg/kg) provided longer lasting relief; however, these doses resulted in transient motor impairment which lasted for 15-30 min post-injection. Systemic KET was most effective in decreasing the behavioral signs of mechanical allodynia and hyperalgesia, followed by cold allodynia, cold stress-induced pain, and spontaneous pain. The present results demonstrate that blockade of NMDA receptors effectively alleviates nociceptive behaviors in a rat model of peripheral neuropathy, substantiating the important role of these receptors in the central sensitization that underlies the maintenance of neuropathic pain. In addition, the ability of KET to reduce significantly a variety of nocifensive behaviors suggests that this clinically safe drug could be used in pain management for neuropathic patients.

    Original languageEnglish (US)
    Pages (from-to)51-62
    Number of pages12
    JournalBrain Research
    Volume715
    Issue number1-2
    DOIs
    StatePublished - Apr 9 1996

    Fingerprint

    Hyperalgesia
    Ketamine
    Peripheral Nervous System Diseases
    Pain
    N-Methyl-D-Aspartate Receptors
    Central Nervous System Sensitization
    Spinal Nerves
    Injections
    Aptitude
    Neuralgia
    Pain Management
    Ligation
    Maintenance
    Pharmaceutical Preparations

    Keywords

    • allodynia
    • hyperalgesia
    • intraperitoneal
    • N-methyl-D-aspartate (NMDA) receptor antagonist
    • nociception
    • non-competitive
    • spontaneous pain

    ASJC Scopus subject areas

    • Neuroscience(all)

    Cite this

    Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy. / Qian, Jin; Brown, Stephen D.; Carlton, Susan M.

    In: Brain Research, Vol. 715, No. 1-2, 09.04.1996, p. 51-62.

    Research output: Contribution to journalArticle

    Qian, Jin ; Brown, Stephen D. ; Carlton, Susan M. / Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy. In: Brain Research. 1996 ; Vol. 715, No. 1-2. pp. 51-62.
    @article{714d6734b1f748c2ae7e866998240527,
    title = "Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy",
    abstract = "The efficacy of ketamine (KET), a non-competitive NMDA receptor-channel blocker, was assessed in relieving nociceptive behaviors in neuropathic rats with tight ligations of the L5 and L6 spinal nerves. The antinociceptive effects of KET were dose- and time-dependent. A systemic injection of 0.01 mg/kg KET transiently (15-30 min) attenuated several nociceptive behaviors, including mechanical allodynia and hyperalgesia, cold allodynia, spontaneous pain, and cold stress-induced pain. Treatment with 1.0 mg/kg KET consistently decreased all nociceptive behaviors for 45-75 min, without noticeable side effects. Higher doses (25 and 50 mg/kg) provided longer lasting relief; however, these doses resulted in transient motor impairment which lasted for 15-30 min post-injection. Systemic KET was most effective in decreasing the behavioral signs of mechanical allodynia and hyperalgesia, followed by cold allodynia, cold stress-induced pain, and spontaneous pain. The present results demonstrate that blockade of NMDA receptors effectively alleviates nociceptive behaviors in a rat model of peripheral neuropathy, substantiating the important role of these receptors in the central sensitization that underlies the maintenance of neuropathic pain. In addition, the ability of KET to reduce significantly a variety of nocifensive behaviors suggests that this clinically safe drug could be used in pain management for neuropathic patients.",
    keywords = "allodynia, hyperalgesia, intraperitoneal, N-methyl-D-aspartate (NMDA) receptor antagonist, nociception, non-competitive, spontaneous pain",
    author = "Jin Qian and Brown, {Stephen D.} and Carlton, {Susan M.}",
    year = "1996",
    month = "4",
    day = "9",
    doi = "10.1016/0006-8993(95)01452-7",
    language = "English (US)",
    volume = "715",
    pages = "51--62",
    journal = "Brain Research",
    issn = "0006-8993",
    publisher = "Elsevier",
    number = "1-2",

    }

    TY - JOUR

    T1 - Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy

    AU - Qian, Jin

    AU - Brown, Stephen D.

    AU - Carlton, Susan M.

    PY - 1996/4/9

    Y1 - 1996/4/9

    N2 - The efficacy of ketamine (KET), a non-competitive NMDA receptor-channel blocker, was assessed in relieving nociceptive behaviors in neuropathic rats with tight ligations of the L5 and L6 spinal nerves. The antinociceptive effects of KET were dose- and time-dependent. A systemic injection of 0.01 mg/kg KET transiently (15-30 min) attenuated several nociceptive behaviors, including mechanical allodynia and hyperalgesia, cold allodynia, spontaneous pain, and cold stress-induced pain. Treatment with 1.0 mg/kg KET consistently decreased all nociceptive behaviors for 45-75 min, without noticeable side effects. Higher doses (25 and 50 mg/kg) provided longer lasting relief; however, these doses resulted in transient motor impairment which lasted for 15-30 min post-injection. Systemic KET was most effective in decreasing the behavioral signs of mechanical allodynia and hyperalgesia, followed by cold allodynia, cold stress-induced pain, and spontaneous pain. The present results demonstrate that blockade of NMDA receptors effectively alleviates nociceptive behaviors in a rat model of peripheral neuropathy, substantiating the important role of these receptors in the central sensitization that underlies the maintenance of neuropathic pain. In addition, the ability of KET to reduce significantly a variety of nocifensive behaviors suggests that this clinically safe drug could be used in pain management for neuropathic patients.

    AB - The efficacy of ketamine (KET), a non-competitive NMDA receptor-channel blocker, was assessed in relieving nociceptive behaviors in neuropathic rats with tight ligations of the L5 and L6 spinal nerves. The antinociceptive effects of KET were dose- and time-dependent. A systemic injection of 0.01 mg/kg KET transiently (15-30 min) attenuated several nociceptive behaviors, including mechanical allodynia and hyperalgesia, cold allodynia, spontaneous pain, and cold stress-induced pain. Treatment with 1.0 mg/kg KET consistently decreased all nociceptive behaviors for 45-75 min, without noticeable side effects. Higher doses (25 and 50 mg/kg) provided longer lasting relief; however, these doses resulted in transient motor impairment which lasted for 15-30 min post-injection. Systemic KET was most effective in decreasing the behavioral signs of mechanical allodynia and hyperalgesia, followed by cold allodynia, cold stress-induced pain, and spontaneous pain. The present results demonstrate that blockade of NMDA receptors effectively alleviates nociceptive behaviors in a rat model of peripheral neuropathy, substantiating the important role of these receptors in the central sensitization that underlies the maintenance of neuropathic pain. In addition, the ability of KET to reduce significantly a variety of nocifensive behaviors suggests that this clinically safe drug could be used in pain management for neuropathic patients.

    KW - allodynia

    KW - hyperalgesia

    KW - intraperitoneal

    KW - N-methyl-D-aspartate (NMDA) receptor antagonist

    KW - nociception

    KW - non-competitive

    KW - spontaneous pain

    UR - http://www.scopus.com/inward/record.url?scp=0029937786&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0029937786&partnerID=8YFLogxK

    U2 - 10.1016/0006-8993(95)01452-7

    DO - 10.1016/0006-8993(95)01452-7

    M3 - Article

    VL - 715

    SP - 51

    EP - 62

    JO - Brain Research

    JF - Brain Research

    SN - 0006-8993

    IS - 1-2

    ER -